Effect of Target Dynamics on Pharmacokinetics of a Novel Therapeutic Antibody against the Epidermal Growth Factor Receptor: Implications for the Mechanisms of Action
Jeroen J. Lammerts van Bueren(Genmab (United States)), Paul W.H.I. Parren(University of Southern Denmark)
Cited by 124
Related Papers
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
|The Journal of Immunology|2010|1k
Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Therapy
|The Journal of Immunology|2004|149
Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63
|Molecular Cancer Therapeutics|2016|131